Purpose
Thyroid transcription factor 1 (TTF-1) expression is a useful predictor of treatment efficacy in advanced non-squamous non-small-cell lung cancer (NSCLC). This study aimed to evaluate whether TTF-1 could predict the effectiveness of chemotherapy versus chemoimmunotherapy in patients with non-squamous NSCLC with programmed death ligand-1 (PD-L1) expression between 1% and 49%.
Materials and Methods
We conducted a retrospective study of patients with NSCLC who were treated with chemotherapy or chemoimmunotherapy between March 2016 and May 2023. The patients had histologically confirmed NSCLC, stage III-IV or postoperative recurrence, TTF-1 measurements, and PD-L1 expression levels between 1% and 49%. Clinical data were analyzed to evaluate the effect of TTF-1 expression on treatment efficacy.
Results
This study included 283 of 624 patients. TTF-1-positive patients showed longer progression-free survival (PFS) and overall survival (OS) (PFS: 6.4 months [95% confidence interval (CI): 5.0−9.4] vs 4.1 months [95% CI: 2.7−6.1], p=0.03, OS: 17.9 months [95% CI: 15.2−28.1] vs 9.4 months [95% CI: 6.3−17.0], p<0.01) in the chemotherapy cohorts (n=93). In the chemoimmunotherapy cohort (n=190), there was no significant difference in PFS and OS between TTF-1-positive and negative groups (PFS: 7.6 months [95% CI: 6.4−11.0] vs 6.0 months [95% CI: 3.6−12.6], p=0.59, OS: 25.0 months [95% CI: 18.0−49.2] vs 21.3 months [95% CI: 9.8−28.8], p=0.09).
Conclusion
In patients with NSCLC with PD-L1 expression between 1% and 49%, TTF-1 expression was a predictor of chemotherapeutic, but not chemoimmunotherapeutic, efficacy.
Songji Choi, Se Hyun Kim, Sejoon Lee, Jeongmin Seo, Minsu Kang, Eun Hee Jung, Sang-A Kim, Koung Jin Suh, Ji Yun Lee, Ji-Won Kim, Jin Won Kim, Jeong-Ok Lee, Yu Jung Kim, Keun-Wook Lee, Jee Hyun Kim, Soo-Mee Bang, Jong Seok Lee
Cancer Res Treat. 2025;57(1):70-82. Published online August 7, 2024
Purpose Some studies suggest that TP53 mutations are associated with the response to immune checkpoint inhibitors (ICI) in patients with non–small cell lung cancer (NSCLC) and also contribute to sex disparities in several cancers. Thus, we hypothesized that TP53 mutations might serve as sex-dependent genomic biomarkers of ICI treatment response in patients with NSCLC.
Materials and Methods Clinical data of 100 patients with metastatic NSCLC treated with ICI monotherapy at Seoul National University Bundang Hospital (SNUBH) were retrospectively reviewed. Genomic and clinical datasets of The Cancer Genome Atlas and an ICI-treated lung cancer cohort (cBioPortal) were also analyzed.
Results In SNUBH cohort, no statistically significant difference was observed in the median progression-free survival (PFS) according to TP53 mutation status (p=0.930); however, female patients with TP53 mutations (MT) had a significantly prolonged median PFS compared to wild-type (WT) (6.1 months in TP53 MT vs. 2.6 months in TP53 WT; p=0.021). Programmed death-ligand 1 (PD-L1) high (≥ 50%) expression was significantly enriched in female patients with TP53 MT (p=0.005). The analysis from publicly available dataset also revealed that females with NSCLC with TP53 MT showed significantly longer PFS than those with TP53 WT (p < 0.001). In The Cancer Genome Atlas analysis, expression of immune-related genes, and tumor mutation burden score in TP53 MT females were higher than in males without TP53 MT.
Conclusion Female patients with NSCLC with TP53 mutations had high PD-L1 expression and showed favorable clinical outcomes following ICI therapy, suggesting a need for further research to explore the role of TP53 mutations for sex disparities in response to ICI therapy.
Purpose
The association between immune-related adverse events (irAEs) and survival outcomes in non–small cell lung cancer (NSCLC) patients treated with programmed death-(ligand) 1 [PD-(L)1] inhibitors remains controversial, partly due to variations in dealing with immortal-time bias (ITB).
Materials and Methods
We retrospectively enrolled 425 advanced NSCLC patients who received anti–PD-(L)1 monotherapy between January 2016 and June 2021, stratifying them into irAE (n=127) and non-irAE (n=298) groups. The primary endpoint was to assess the impact of irAEs on progression-free survival (PFS) and overall survival (OS). Landmark (2-, 3-, 6-, and 9-month) and time-dependent Cox analyses were performed to eliminate ITB.
Results
With a median follow-up of 38.8 months, the occurrence of overall irAEs was significantly associated with superior PFS (11.2 vs. 3.4 months, p < 0.001) and OS (31.4 vs. 14.0 months, p < 0.001), which persisted in landmark and time-dependent Cox analyses. For the main organ-specific irAEs, skin, thyroid, and hepatic irAEs, respectively, showed significantly improved survival compared to the non-irAE group, whereas pneumonitis did not. Single-organ irAEs had the best outcomes compared with multi-organ or no irAE, which also held across subgroups of skin, thyroid, and hepatic irAEs. Moreover, severe grade irAEs and immunotherapy discontinuation had a detrimental effect on survival, systemic steroid therapy showed little effect, while immunotherapy resumption had tolerable safety and a trend of improved survival.
Conclusion
After adequately adjusting ITB, the occurrence of overall irAEs predicts for favorable efficacy of anti–PD-(L)1 monotherapy in NSCLC, with better outcomes observed in patients with skin, thyroid, or hepatic irAEs, particularly those with single-organ involvement.
Citations
Citations to this article as recorded by
Management, biomarkers and prognosis in people developing endocrinopathies associated with immune checkpoint inhibitors Shintaro Iwama, Tomoko Kobayashi, Hiroshi Arima Nature Reviews Endocrinology.2025;[Epub] CrossRef
Development of pituitary dysfunction and destructive thyroiditis is associated with better survival in non-small cell lung cancer patients treated with programmed cell death-1 inhibitors: a prospective study with immortal time bias correction Koji Suzuki, Tomoko Kobayashi, Tetsushi Izuchi, Koki Otake, Masahiko Ando, Tomoko Handa, Takashi Miyata, Mariko Sugiyama, Takeshi Onoue, Daisuke Hagiwara, Hidetaka Suga, Ryoichi Banno, Tetsunari Hase, Megumi Inoue, Makoto Ishii, Hiroshi Arima, Shintaro Iw Frontiers in Endocrinology.2024;[Epub] CrossRef
Associations between Immune-related Adverse Events and Prognosis in Cancer Patients Receiving Immune Checkpoint Inhibitor Therapy Yusuke Inoue, Naoki Inui Internal Medicine.2024;[Epub] CrossRef
The impact of immune-related adverse events on the outcome of advanced gastric cancer patients with immune checkpoint inhibitor treatment Tianhang Zhang, Haitao Lv, Jiasong Li, Shasha Zhang, Jingjing Zhang, Siqi Wang, Yingnan Wang, Zhanjun Guo Frontiers in Immunology.2024;[Epub] CrossRef
Purpose The programmed death-ligand 1 (PD-L1) SP142 assay identifies patients with triple-negative breast cancer (TNBC) who are most likely to respond to the anti–PD-L1 agent atezolizumab. We aimed to compare PD-L1 (SP142) expression between primary and recurrent/metastatic TNBCs and elucidate the clinicopathological features associated with its expression.
Materials and Methods Primary and recurrent/metastatic TNBCs tested with PD-L1 (SP142) were collected, and clinicopathological information of these cases was obtained through a review of slides and medical records.
Results PD-L1 (SP142) positivity was observed in 50.9% (144/283) of primary tumors and 37.8% (31/82) of recurrent/metastatic TNBCs with a significant difference. Recurrent or metastatic sites were associated with PD-L1 positivity, with high PD-L1 positivity in the lung, breast, and soft tissues, and low positivity in the bone, skin, liver, and brain. When comparing PD-L1 expression between primary and matched recurrent/metastatic TNBCs using 55 paired samples, 20 cases (36.4%) showed discordance; 10 cases revealed positive conversion, and another 10 cases revealed negative conversion during metastatic progression. In primary TNBCs, PD-L1 expression was associated with a higher histologic grade, lower T category, pushing border, and higher tumor-infiltrating lymphocyte infiltration. In survival analyses, PD-L1 positivity, especially high positivity, was found to be associated with favorable prognosis of patients.
Conclusion PD-L1 (SP142) expression was lower in recurrent/metastatic TNBCs, and substantial cases showed discordance in its expression between primary and recurrent/metastatic sites, suggesting that multiple sites may need to be tested for PD-L1 (SP142) when considering atezolizumab therapy. PD-L1 (SP142)–positive TNBCs seems to be associated with favorable clinical outcomes.
Citations
Citations to this article as recorded by
Solamargine inhibits gastric cancer progression via inactivation of STAT3/PD‑L1 signaling Xiongxiang Liu, Lin Song, Wen Liu, Bin Liu, Lang Liu, Yao Su Molecular Medicine Reports.2024;[Epub] CrossRef
Prevalence of Programmed Death-Ligand 1 Positivity Using SP142 in Patients With Advanced Stage Triple-Negative Breast Cancer in Malaysia: A Cross-Sectional Study Pathmanathan Rajadurai, Ning Yi Yap, Seow Fan Chiew, Reena Rahayu Md Zin, Suria Hayati Md Pauzi, Aniqah Shamimi Binti Jaafar, Azyani Yahaya, Lai Meng Looi Journal of Breast Cancer.2024; 27(6): 362. CrossRef
Purpose
The objective of this study was to describe and analyze the clinicopathological features of primary choriocarcinoma (PCC) observed in male patients treated at the Samsung Medical Center between 1996 and 2020.
Materials and Methods
We reviewed the clinical records of 14 male patients with PCC retrospectively to assess their demographic, histological, and clinical characteristics at the time of diagnosis as well as identify the treatment outcomes.
Results
The median age of the patients was 33 years. The primary tumor site was the testicles in seven cases (50%), the mediastinum in six cases (43%), and the brain in one case (7%). The most common metastatic site was the lungs (79%), followed by the brain (43%). All patients with PCC received cytotoxic chemotherapy. Twelve patients had records of their response to cytotoxic chemotherapy; of these 12 patients, eight (8/12, 67%) achieved an objective response, and four (4/12, 33%) achieved stable disease response as the best response during chemotherapy.
Conclusion
It is known that most male PCC patients eventually develop resistance to cytotoxic chemotherapy and die. Factors such as poor response to chemotherapy, high disease burden, brain metastasis, and hemoptysis at the time of diagnosis are associated with shorter survival time in male PCC patients. Programmed death-1/programmed death-ligand 1 blockade therapy can be a salvage treatment for chemotherapy-resistant male PCC patients.
Citations
Citations to this article as recorded by
Combination chemotherapy with sintilimab for treatment of a male patient with primary pulmonary choriocarcinoma: a case report and literature review Xiaojing Liang, Guoqing Xu, Jisong Zhang, Li Xu, Liangliang Dong, Xiaoyue Wang, Weidong Han, Enguo Chen Frontiers in Immunology.2025;[Epub] CrossRef
Primary retroperitoneal choriocarcinoma with lung and liver metastasis in a male patient: case report Guimei Wang, Ronghui Li Oncologie.2024; 26(1): 167. CrossRef
A poor prognostic male choriocarcinoma with multiple systemic metastases: a case report and the literature review Wenpeng Huang, Zuohuan Zheng, Zheng Bao, Xiaoyan Xiao, Liming Li, Zhaonan Sun, Lei Kang Frontiers in Medicine.2024;[Epub] CrossRef
Pediatric primary extragonadal choriocarcinoma - A study on male patients at a single tertiary medical institution Jui-Ju Tseng, Chi-Yen Chen, Chiung-Wen Liang, Fang-Liang Huang Pediatrics & Neonatology.2024;[Epub] CrossRef
Comparative analysis of testicular and nontesticular choriocarcinoma: a population-based study Sakhr Alshwayyat, Maen S. Soudi, Marwa T. Qaddoura, Tala A. Alshwayyat, Obada Ababneh, Hamdah Hanifa, Ramez M. Odat, Rami S. AlAzab Annals of Medicine & Surgery.2024; 86(12): 6951. CrossRef
The tumor or inflammation? a case report on primary pulmonary choriocarcinoma Na Wang, Nan Zhang, Xinyue Zhang, Yuanyuan Wang, Yajie Fu, Lingfei Guo, Changhu Liang, Mengru Yu Frontiers in Oncology.2023;[Epub] CrossRef
Pure testicular choriocarcinoma, a rare and highly malignant subtype with challenging treatment: A case report and review of the literature Na Lei, Li-Li Lei, Chao-Hong Wang, Chao-Rong Mei Molecular and Clinical Oncology.2023;[Epub] CrossRef
Case Report: Treatment of primary pulmonary choriocarcinoma with lung lobectomy and adjuvant chemotherapy Andrea M. Johnson, Christiana M. Johnson, Zena Khalil, Maria Stitzel, Deanna Teoh Gynecologic Oncology Reports.2022; 43: 101064. CrossRef
Extragonadal Germ Cell Tumors of the Mediastinum and Retroperitoneum David Aguiar Bujanda, Daniel Pérez Cabrera, Laura Croissier Sánchez American Journal of Clinical Oncology.2022; 45(12): 493. CrossRef
Purpose
Combination of radiotherapy and immune checkpoint blockade such as programmed death- 1 (PD-1) or programmed death-ligand 1 (PD-L1) blockade is being actively tested in clinical trial. We aimed to identify a subset of patients that could potentially benefit from this strategy using The Cancer Genome Atlas (TCGA) dataset for glioblastoma (GBM).
Materials and Methods
A total of 399 cases were clustered into radiosensitive versus radioresistant (RR) groups based on a radiosensitivity gene signature and were also stratified as PD-L1 high versus PD-L1 low groups by expression of CD274 mRNA. Differential and integrated analyses with expression and methylation data were performed. CIBERSORT was used to enumerate the immune repertoire that resulted from transcriptome profiles.
Results
We identified a subset of GBM, PD-L1-high-RR group which showed worse survival compared to others. In PD-L1-high-RR, differentially expressed genes (DEG) were highly enriched for immune response and mapped into activation of phosphoinositide 3-kinase–AKT and mitogen-activated protein kinase (MAPK) signaling pathways. Integration of DEG and differentially methylated region identified that the kinase MAP3K8-involved in T-cell receptor signaling was upregulated and BAI1, a factor which inhibits angiogenesis, was silenced. CIBERSORT showed that a higher infiltration of the immune repertoire, which included M2 macrophages and regulatory T cells.
Conclusion
Taken together, PD-L1-high-RR group could potentially benefit from radiotherapy combined with PD-1/PD-L1 blockade and angiogenesis inhibition.
Citations
Citations to this article as recorded by
Clinical Biomarkers of Tumour Radiosensitivity and Predicting Benefit from Radiotherapy: A Systematic Review Christopher W. Bleaney, Hebatalla Abdelaal, Mark Reardon, Carmel Anandadas, Peter Hoskin, Ananya Choudhury, Laura Forker Cancers.2024; 16(10): 1942. CrossRef
A retrospective cohort study of neoadjuvant chemoradiotherapy combined with immune checkpoint inhibitors in locally advanced rectal cancer Zhuo Chen, Zhuoling Zou, Min Qian, Qin Xu, Guojuan Xue, Juan Yang, Tinglan Luo, Lianjie Hu, Bin Wang Translational Oncology.2024; 44: 101955. CrossRef
Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives Hao Lin, Chaxian Liu, Ankang Hu, Duanwu Zhang, Hui Yang, Ying Mao Journal of Hematology & Oncology.2024;[Epub] CrossRef
PSF-lncRNA interaction as a target for novel targeted anticancer therapies Ren Liu, Xiaojing Wang, Min Zhou, Jingfang Zhai, Jie Sun Biomedicine & Pharmacotherapy.2024; 180: 117491. CrossRef
Bladder Cancer Treatments in the Age of Personalized Medicine: A Comprehensive Review of Potential Radiosensitivity Biomarkers Charbel Feghaly, Rafka Challita, Hanine Bou Hadir, Tala Mobayed, Tarek Al Bitar, Mohammad Harbi, Hala Ghorayeb, Rana El-Hassan, Larry Bodgi Biomarker Insights.2024;[Epub] CrossRef
Improving the efficacy of combined radiotherapy and immunotherapy: focusing on the effects of radiosensitivity Zhiru Gao, Qian Zhao, Yiyue Xu, Linlin Wang Radiation Oncology.2023;[Epub] CrossRef
In Vivo Evaluation of Near-Infrared Fluorescent Probe for TIM3 Targeting in Mouse Glioma Michael Zhang, Quan Zhou, Chinghsin Huang, Carmel T. Chan, Wei Wu, Gordon Li, Michael Lim, Sanjiv S. Gambhir, Heike E. Daldrup-Link Molecular Imaging and Biology.2022; 24(2): 280. CrossRef
Relationship between Macrophage and Radiosensitivity in Human Primary and Recurrent Glioblastoma: In Silico Analysis with Publicly Available Datasets Bum-Sup Jang, In Ah Kim Biomedicines.2022; 10(2): 292. CrossRef
Optimal management of recurrent and metastatic upper tract urothelial carcinoma: Implications of intensity modulated radiation therapy Mi Sun Kim, Woong Sub Koom, Jae Ho Cho, Se-Young Kim, Ik Jae Lee Radiation Oncology.2022;[Epub] CrossRef
Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence Daniel Kreatsoulas, Chelsea Bolyard, Bill X. Wu, Hakan Cam, Pierre Giglio, Zihai Li Journal of Hematology & Oncology.2022;[Epub] CrossRef
The Next Frontier in Health Disparities—A Closer Look at Exploring Sex Differences in Glioma Data and Omics Analysis, from Bench to Bedside and Back Maria Diaz Rosario, Harpreet Kaur, Erdal Tasci, Uma Shankavaram, Mary Sproull, Ying Zhuge, Kevin Camphausen, Andra Krauze Biomolecules.2022; 12(9): 1203. CrossRef
Immunosuppression in Gliomas via PD-1/PD-L1 Axis and Adenosine Pathway Thamiris Becker Scheffel, Nathália Grave, Pedro Vargas, Fernando Mendonça Diz, Liliana Rockenbach, Fernanda Bueno Morrone Frontiers in Oncology.2021;[Epub] CrossRef
The Combination of Radiotherapy With Immunotherapy and Potential Predictive Biomarkers for Treatment of Non-Small Cell Lung Cancer Patients Lu Meng, Jianfang Xu, Ying Ye, Yingying Wang, Shilan Luo, Xiaomei Gong Frontiers in Immunology.2021;[Epub] CrossRef
Explore association of genes in PDL1/PD1 pathway to radiotherapy survival benefit based on interaction model strategy Junjie Shen, Jingfang Liu, Huijun Li, Lu Bai, Zixuan Du, Ruirui Geng, Jianping Cao, Peng Sun, Zaixiang Tang Radiation Oncology.2021;[Epub] CrossRef
Combination of Radiosensitivity Gene Signature and PD-L1 Status Predicts Clinical Outcome of Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma: A Study Based on The Cancer Genome Atlas Dataset Dongjun Dai, Yinglu Guo, Yongjie Shui, Jinfan Li, Biao Jiang, Qichun Wei Frontiers in Molecular Biosciences.2021;[Epub] CrossRef
Prognostic Values of Radiosensitivity Genes and CD19 Status in Gastric Cancer: A Retrospective Study Using TCGA Database
Li-Bo Liang, Xin-Yan Huang, He He, Ji-Yan Liu Pharmacogenomics and Personalized Medicine.2020; Volume 13: 365. CrossRef
Gene signature based on B cell predicts clinical outcome of radiotherapy and immunotherapy for patients with lung adenocarcinoma Linzhi Han, Hongjie Shi, Yuan Luo, Wenjie Sun, Shuying Li, Nannan Zhang, Xueping Jiang, Yan Gong, Conghua Xie Cancer Medicine.2020; 9(24): 9581. CrossRef
Purpose
This study aimed to investigate the potential systemic antitumor effects of stereotactic ablative radiotherapy (SABR) and apatinib (a novel vascular endothelial growth factor receptor 2 inhibitor) via reversing the immunosuppressive tumor microenvironment for lung carcinoma.
Materials and Methods
Lewis lung cancer cells were injected into C57BL/6 mice in the left hindlimb (primary tumor; irradiated) and in the right flank (secondary tumor; nonirradiated). When both tumors grew to the touchable size, mice were randomly divided into eight treatment groups. These groups received normal saline or three distinct doses of apatinib (50 mg/kg, 150 mg/kg, and 200 mg/kg) daily for 7 days, in combination with a single dose of 15 Gy radiotherapy or not to the primary tumor. The further tumor growth/regression of mice were followed and observed.
Results
For the single 15 Gy modality, tumor growth delay could only be observed at the primary tumor. When combining SABR and apatinib 200 mg/kg, significant retardation of both primary and secondary tumor growth could be observed, indicated an abscopal effect was induced. Mechanism analysis suggested that programmed death-ligand 1 expression increased with SABR was counteract by additional apatinib therapy. Furthermore, when apatinib was combined with SABR, the composition of immune cells could be changed. More importantly, this two-pronged approach evoked tumor antigen–specific immune responses and the mice were resistant to another tumor rechallenge, finally, long-term survival was improved.
Conclusion
Our results suggested that the tumor microenvironment could be managed with apatinib, which was effective in eliciting an abscopal effect induced by SABR.
Citations
Citations to this article as recorded by
Comparison of Efficacy and Safety of Different Second-line Therapies for Patients With Advanced Thymic Carcinoma K. Shao, Y. Hao, M. Xu, Z. Shi, G. Lin, C. Xu, Y. Zhang, Z. Song Clinical Oncology.2024; 36(11): 710. CrossRef
Immune effect and prognosis of transcatheter arterial chemoembolization and tyrosine kinase inhibitors therapy in patients with hepatocellular carcinoma Yuan Guo, Ru-Chun Li, Wei-Li Xia, Xiong Yang, Wen-Bo Zhu, Fang-Ting Li, Hong-Tao Hu, Hai-Liang Li World Journal of Gastrointestinal Oncology.2024; 16(7): 3256. CrossRef
A disintegrin and metalloproteinase domain 10 expression inhibition by the small molecules adenosine, cordycepin and N6, N6-dimethyladenosine and immune regulation in malignant cancers Wenqian Zhang, Jiewen Fu, Jiaman Du, Xiaoyan Liu, Jingliang Cheng, Chunli Wei, Youhua Xu, Junjiang Fu Frontiers in Immunology.2024;[Epub] CrossRef
Antiangiogenic Treatment Facilitates the Abscopal Effect of Radiation Therapy Combined With Anti-PD-1 in Hepatocellular Carcinoma Hailong Sheng, Yongyi Luo, Liting Zhong, Zhiyi Wang, Zhichao Sun, Xinna Gao, Xinrong He, Zhenru Zhu, Dehua Wu, Jingyuan Sun, Chuanhui Cao International Journal of Radiation Oncology*Biology*Physics.2024;[Epub] CrossRef
Low‐ dose Apatinib promotes vascular normalization and hypoxia reduction and sensitizes radiotherapy in lung cancer Shanshan Jiang, Yue Zhou, Liqing Zou, Li Chu, Xiao Chu, Jianjiao Ni, Yida Li, Tiantian Guo, Xi Yang, Zhengfei Zhu Cancer Medicine.2023; 12(4): 4434. CrossRef
Local Destruction of Tumors and Systemic Immune Effects Karl-Göran Tranberg Frontiers in Oncology.2021;[Epub] CrossRef
A novel role for apatinib in enhancing radiosensitivity in non-small cell lung cancer cells by suppressing the AKT and ERK pathways Lin Li, Yuexian Li, Huawei Zou PeerJ.2021; 9: e12356. CrossRef
Purpose
Pancreatic cancer (PC) is one of the most lethal cancers worldwide, but there are currently no effective treatments. The DNA damage response (DDR) is under investigation for the development of novel anti-cancer drugs. Since DNA repair pathway alterations have been found frequently in PC, the purpose of this study was to test the DDR-targeting strategy in PC using WEE1 and ATM inhibitors.
Materials and Methods
We performed in vitro experiments using a total of ten human PC cell lines to evaluate antitumor effect of AZD1775 (WEE1 inhibitor) alone or combination with AZD0156 (ATM inhibitor). We established Capan-1–mouse model for in vivo experiments to confirm our findings.
Results
In our research, we found that WEE1 inhibitor (AZD1775) as single agent showed anti-tumor effects in PC cells, however, targeting WEE1 upregulated p-ATM level. Here, we observed that co-targeting of WEE1 and ATM acted synergistically to reduce cell proliferation and migration, and to induce DNA damage in vitro. Notably, inhibition of WEE1 or WEE1/ATM downregulated programmed cell death ligand 1 expression by blocking glycogen synthase kinase-3β serine 9 phosphorylation and decrease of CMTM6 expression. In Capan-1 mouse xenograft model, AZD1775 plus AZD0156 (ATM inhibitor) treatment reduced tumor growth and downregulated tumor expression of programmed cell death ligand 1, CMTM6, CD163, and CXCR2, all of which contribute to tumor immune evasion.
Conclusion
Dual blockade of WEE1 and ATM might be a potential therapeutic strategy for PC. Taken toget
Citations
Citations to this article as recorded by
The Killer’s Web: Interconnection between Inflammation, Epigenetics and Nutrition in Cancer Marisabel Mecca, Simona Picerno, Salvatore Cortellino International Journal of Molecular Sciences.2024; 25(5): 2750. CrossRef
The molecular crosstalk between innate immunity and DNA damage repair/response: Interactions and effects in cancers Sahar Omidvar, Vahid Vahedian, Zahra Sourani, Davood Yari, Mehrdad Asadi, Negin Jafari, Lida Khodavirdilou, Molood Bagherieh, Moein Shirzad, Vahid Hosseini Pathology - Research and Practice.2024; 260: 155405. CrossRef
Progress of ATM inhibitors: opportunities and challenges Shan Du, Qi Liang, Jianyou Shi European Journal of Medicinal Chemistry.2024; : 116781. CrossRef
A prognostic risk model for ovarian cancer based on gene expression profiles from gene expression omnibus database Wei Fan, Xiaoyun Chen, Ruiping Li, Rongfang Zheng, Yunyun Wang, Yuzhen Guo Biochemical Genetics.2023; 61(1): 138. CrossRef
PGD2 displays distinct effects in diffuse large B-cell lymphoma depending on different concentrations Shunfeng Hu, Tiange Lu, Juanjuan Shang, Yiqing Cai, Mengfei Ding, Xiangxiang Zhou, Xin Wang Cell Death Discovery.2023;[Epub] CrossRef
The Landscape and Therapeutic Targeting of BRCA1, BRCA2 and Other DNA Damage Response Genes in Pancreatic Cancer Ioannis A. Voutsadakis, Antonia Digklia Current Issues in Molecular Biology.2023; 45(3): 2105. CrossRef
Bosutinib high density lipoprotein nanoformulation has potent tumour radiosensitisation effects Pouya Dehghankelishadi, Parisa Badiee, Michelle F. Maritz, Nicole Dmochowska, Benjamin Thierry Journal of Nanobiotechnology.2023;[Epub] CrossRef
Could Inhibiting the DNA Damage Repair Checkpoint Rescue Immune-Checkpoint-Inhibitor-Resistant Endometrial Cancer? Yinuo Li, Xiangyu Wang, Xin Hou, Xiangyi Ma Journal of Clinical Medicine.2023; 12(8): 3014. CrossRef
The mechanism and clinical application of DNA damage repair inhibitors combined with immune checkpoint inhibitors in the treatment of urologic cancer Deqian Xie, Bowen Jiang, Shijin Wang, Qifei Wang, Guangzhen Wu Frontiers in Cell and Developmental Biology.2023;[Epub] CrossRef
The DNA Damage Response and Inflammation in Cancer Vanessa Klapp, Beatriz Álvarez-Abril, Giuseppe Leuzzi, Guido Kroemer, Alberto Ciccia, Lorenzo Galluzzi Cancer Discovery.2023; 13(7): 1521. CrossRef
CMTM6, a potential immunotherapy target Jie Liang, Shaohua Li, Wei Li, Wei Rao, Shuo Xu, Haining Meng, Fengqi Zhu, Dongchang Zhai, Mengli Cui, Dan Xu, Jinzhen Cai, Bei Zhang Journal of Cancer Research and Clinical Oncology.2022; 148(1): 47. CrossRef
Loss of CMTM6 promotes DNA damage-induced cellular senescence and antitumor immunity Hanfeng Wang, Yang Fan, Weihao Chen, Zheng Lv, Shengpan Wu, Yundong Xuan, Chenfeng Wang, Yongliang Lu, Tao Guo, Donglai Shen, Fan Zhang, Qingbo Huang, Yu Gao, Hongzhao Li, Xin Ma, Baojun Wang, Yan Huang, Xu Zhang OncoImmunology.2022;[Epub] CrossRef
Cell cycle checkpoints and beyond: Exploiting the ATR/CHK1/WEE1 pathway for the treatment of PARP inhibitor–resistant cancer Nitasha Gupta, Tzu-Ting Huang, Sachi Horibata, Jung-Min Lee Pharmacological Research.2022; 178: 106162. CrossRef
DNA damage response inhibition‐based combination therapies in cancer treatment: Recent advances and future directions Tianen Chen, Suparat Tongpeng, Ziyi Lu, Win Topatana, Sarun Juengpanich, Shijie Li, Jiahao Hu, Jiasheng Cao, Cheeshin Lee, Yitong Tian, Mingyu Chen, Xiujun Cai Aging and Cancer.2022; 3(1): 44. CrossRef
The clinical and prognostic significance of CMTM6/PD-L1 in oncology Mahmoud Mohammad Yaseen, Nizar Mohammad Abuharfeil, Homa Darmani Clinical and Translational Oncology.2022; 24(8): 1478. CrossRef
Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment Giulia Petroni, Aitziber Buqué, Lisa M. Coussens, Lorenzo Galluzzi Nature Reviews Drug Discovery.2022; 21(6): 440. CrossRef
CMTM6 as a master regulator of PD-L1 Mahmoud Mohammad Yaseen, Nizar Mohammad Abuharfeil, Homa Darmani Cancer Immunology, Immunotherapy.2022; 71(10): 2325. CrossRef
Targeting protein kinases benefits cancer immunotherapy Zhengkun Zhang, Lang Bu, Junhang Luo, Jianping Guo Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2022; 1877(4): 188738. CrossRef
CMTM6 and CMTM4 as two novel regulators of PD-L1 modulate the tumor microenvironment Tong Zhang, Haixiang Yu, Xiangpeng Dai, Xiaoling Zhang Frontiers in Immunology.2022;[Epub] CrossRef
The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy Congqi Shi, Kaiyu Qin, Anqi Lin, Aimin Jiang, Quan Cheng, Zaoqu Liu, Jian Zhang, Peng Luo Journal of Experimental & Clinical Cancer Research.2022;[Epub] CrossRef
CMTM6 as a candidate risk gene for cervical cancer: Comprehensive bioinformatics study Xiaoting Huang, Wei Liu, Chunshan Liu, Jijie Hu, Baiyao Wang, Anbang Ren, Xiaona Huang, Yawei Yuan, Jinquan Liu, Mingyi Li Frontiers in Molecular Biosciences.2022;[Epub] CrossRef
DNA damaging agents and DNA repair: From carcinogenesis to cancer therapy Larissa Costa de Almeida, Felipe Antunes Calil, João Agostinho Machado-Neto, Leticia Veras Costa-Lotufo Cancer Genetics.2021; 252-253: 6. CrossRef
Immunomodulation by targeted anticancer agents Giulia Petroni, Aitziber Buqué, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi Cancer Cell.2021; 39(3): 310. CrossRef
Targeting WEE1 by adavosertib inhibits the malignant phenotypes of hepatocellular carcinoma Jian Chen, Xing Jia, Zequn Li, Wenfeng Song, Cheng Jin, Mengqiao Zhou, Haiyang Xie, Shusen Zheng, Penghong Song Biochemical Pharmacology.2021; 188: 114494. CrossRef
WEE1 inhibition reverses trastuzumab resistance in HER2-positive cancers Mei-Hua Jin, Ah-Rong Nam, Ju-Hee Bang, Kyoung-Seok Oh, Hye-Rim Seo, Jae-Min Kim, Jeesun Yoon, Tae-Yong Kim, Do-Youn Oh Gastric Cancer.2021; 24(5): 1003. CrossRef
ATR inhibition amplifies antitumor effects of olaparib in biliary tract cancer Ah-Rong Nam, Jeesun Yoon, Mei-Hua Jin, Ju-Hee Bang, Kyoung-Seok Oh, Hye-Rim Seo, Jae-Min Kim, Tae-Yong Kim, Do-Youn Oh Cancer Letters.2021; 516: 38. CrossRef
Development of Immunotherapy Combination Strategies in Cancer Timothy A. Yap, Eileen E. Parkes, Weiyi Peng, Justin T. Moyers, Michael A. Curran, Hussein A. Tawbi Cancer Discovery.2021; 11(6): 1368. CrossRef
Therapeutic resistance in pancreatic ductal adenocarcinoma: Current challenges and future opportunities Aditi Jain, Vikas Bhardwaj World Journal of Gastroenterology.2021; 27(39): 6527. CrossRef
A steroidal saponin isolated from Allium chinense simultaneously induces apoptosis and autophagy by modulating the PI3K/Akt/mTOR signaling pathway in human gastric adenocarcinoma Jingwen Xu, Mingmei Zhang, Xiaoying Lin, Yihai Wang, Xiangjiu He Steroids.2020; : 108672. CrossRef
Junghoon Shin, Jin-Haeng Chung, Se Hyun Kim, Kyu Sang Lee, Koung Jin Suh, Ji Yun Lee, Ji-Won Kim, Jeong-Ok Lee, Jin-Won Kim, Yu-Jung Kim, Keun-Wook Lee, Jee Hyun Kim, Soo-Mee Bang, Jong-Seok Lee
Cancer Res Treat. 2019;51(3):1086-1097. Published online November 5, 2018
Purpose
Programmed death-1 (PD-1)/PD-1 ligand (PD-L1) axis blockades have revolutionized the treatment of advanced non-small cell lung cancer (NSCLC). We assessed the effect of platinum-based chemotherapy on tumor PD-L1 expression and its clinical implications.
Materials and Methods
We used immunohistochemistry to retrospectively evaluate the percentage of tumor cells with membranous PD-L1 staining (tumor proportion score) in paired tumor specimens obtained before and after platinum-based neoadjuvant chemotherapy (NACT) in 86 patients with NSCLC. We analyzed the correlation between the change in PD-L1 tumor proportion score and clinicopathologic characteristics, response to NACT, and survival.
Results
The PD-L1 tumor proportion score increased in a significant proportion of patients with NSCLC after platinum-based NACT (Wilcoxon signed-rank test, p=0.002). That pattern was consistent across clinically defined subgroups except for patients with partial response to NACT. Tumors from 26 patients (30.2%) were PD-L1‒negative before NACT but PD-L1-positive after NACT, whereas the reverse pattern occurred in six patients (7%) (McNemar’s test, p < 0.001). Increase in PD-L1 tumor proportion score was significantly associated with lack of response to NACT (Fisher exact test, p=0.015). There was a tendency, albeit not statistically significant, for patients with an increase in PD-L1 tumor proportion score to have shorter survival.
Conclusion
Tumor PD-L1 expression increased after platinum-based NACT in a significant proportion of patients with NSCLC. Increase in tumor PD-L1 expression may predict poor clinical outcome.
Citations
Citations to this article as recorded by
Potential Predictive Immune and Metabolic Biomarkers of Tumor Microenvironment Regarding Pathological and Clinical Response in Esophageal Cancer After Neoadjuvant Chemoradiotherapy: A Systematic Review H. H. Wang, E. N. Steffens, G. Kats-Ugurlu, B. van Etten, J. G. M. Burgerhof, G. A. P. Hospers, J. T. M. Plukker Annals of Surgical Oncology.2024; 31(1): 433. CrossRef
Redetermination of PD-L1 expression after chemio-radiation in locally advanced PDL1 negative NSCLC patients: retrospective multicentric analysis Patrizia Ciammella, Salvatore Cozzi, Paolo Borghetti, Marco Galaverni, Valerio Nardone, Maria Paola Ruggieri, Matteo Sepulcri, Vieri Scotti, Alessio Bruni, Francesca Zanelli, Roberto Piro, Elena Tagliavini, Andrea Botti, Federico Iori, Emanuele Alì, Chiar Frontiers in Oncology.2024;[Epub] CrossRef
First exploration of the on-treatment changes in tumor and organ uptake of a radiolabeled anti PD-L1 antibody during chemoradiotherapy in patients with non-small cell lung cancer using whole body PET Johanna E E Pouw, Sayed M S Hashemi, Marc C Huisman, Jessica E Wijngaarden, Maarten Slebe, Daniela E Oprea-Lager, Gerben J C Zwezerijnen, Danielle Vugts, Ezgi B Ulas, Tanja D de Gruijl, Teodora Radonic, Suresh Senan, C Willemien Menke-van der Houven van O Journal for ImmunoTherapy of Cancer.2024; 12(2): e007659. CrossRef
Use of non-small cell lung cancer multicellular tumor spheroids to study the impact of chemotherapy Pauline Hulo, Sophie Deshayes, Judith Fresquet, Anne-Laure Chéné, Stéphanie Blandin, Nicolas Boisgerault, Jean-François Fonteneau, Lucas Treps, Marc G Denis, Jaafar Bennouna, Delphine Fradin, Elvire Pons-Tostivint, Christophe Blanquart Respiratory Research.2024;[Epub] CrossRef
Alteration of PD-L1 (SP142) status after neoadjuvant chemotherapy and its clinical significance in triple-negative breast cancer Ji Won Woo, Eun Kyung Han, Koung Jin Suh, Se Hyun Kim, Jee Hyun Kim, So Yeon Park Breast Cancer Research and Treatment.2024; 207(2): 301. CrossRef
Transforming Lung Cancer Management: A Promising Case Study of Immune Checkpoint Inhibitor Success Following a Multidisciplinary Approach Tadashi Nishimura, Hajime Fujimoto, Takumi Fujiwara, Tomohito Okano, Taro Yasuma, Esteban C. Gabazza, Hidenori Ibata, Tetsu Kobayashi Diagnostics.2024; 14(19): 2159. CrossRef
Cryoablation plus chemotherapy regimen enhance anti-tumor immune response in a mouse model of Lewis lung cancer Hua Duan, Li Yang, Xueni Fang, Shaohua Yan, Yang Cao, Bingli Qiao, Tian Zhou, Kaiwen Hu International Journal of Hyperthermia.2024;[Epub] CrossRef
Increased Tumor Mutation Burden Levels and Sensitivity of Non–Small Cell Lung Cancer to PD-L1 Blockade—Reply Biagio Ricciuti, Xinan Wang, Mark M. Awad JAMA Oncology.2023; 9(4): 570. CrossRef
Add-On Effect of Hemagglutinating Virus of Japan Envelope Combined with Chemotherapy or Immune Checkpoint Inhibitor against Malignant Pleural Mesothelioma: An In Vivo Study Kazuma Sakura, Masao Sasai, Soichiro Funaki, Yasushi Shintani, Meinoshin Okumura, Yasufumi Kaneda Cancers.2023; 15(3): 929. CrossRef
Predictive biomarkers for PD-1/PD-L1 checkpoint inhibitor response in NSCLC: an analysis of clinical trial and real-world data WeiQing Venus So, David Dejardin, Eva Rossmann, Jehad Charo Journal for ImmunoTherapy of Cancer.2023; 11(2): e006464. CrossRef
Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14 D. König, S. Savic Prince, S. Hayoz, P. Zens, S. Berezowska, W. Jochum, E. Stauffer, V. Braunersreuther, B. Trachsel, S. Thierstein, M. Mark, S. Schmid, A. Curioni-Fontecedro, A. Addeo, I. Opitz, M. Guckenberger, M. Früh, D.C. Betticher, H.-B. Ris, R. Stu ESMO Open.2023; 8(4): 101595. CrossRef
Poliovirus receptor (PVR) mediates carboplatin-induced PD-L1 expression in non-small-cell lung cancer cells Chen Fu, Zongcai Liu, Taixue An, Haixia Li, Xiumei Hu, Xin Li, Xinyao Liu, Danjuan Wu, Ruyi Zhang, Kui Li, Yurong Qiu, Haifang Wang Biochimica et Biophysica Acta (BBA) - General Subjects.2023; 1867(10): 130439. CrossRef
Remarkable Response to Immune Checkpoint Inhibitor Monotherapy in an EGFR-Mutant Pulmonary Adenocarcinoma Patient With 0% Expression of PD-L1 Tetsuo Fujita, Hiroyuki Amano, Makoto Nakamura, Satoshi Hirano, Sukeyuki Nakamura Journal of Thoracic Oncology.2023; 18(9): e93. CrossRef
Effect of Chemotherapeutics on In Vitro Immune Checkpoint Expression in Non-Small Cell Lung Cancer Yu Zhao, Zhe Wang, Xiuhuan Shi, Ting Liu, Wenwen Yu, Xiubao Ren, Hua Zhao Technology in Cancer Research & Treatment.2023;[Epub] CrossRef
The Role of Regulatory T Cells in Cancer Treatment Resistance Anna Dąbrowska, Magdalena Grubba, Amar Balihodzic, Olga Szot, Bartosz Kamil Sobocki, Adrian Perdyan International Journal of Molecular Sciences.2023; 24(18): 14114. CrossRef
Redirecting Chemotherapeutics to the Endoplasmic Reticulum Increases Tumor Immunogenicity and Potentiates Anti‐PD‐L1 Therapy Yucheng Xiang, Liqiang Chen, Chendong Liu, Xiaoli Yi, Lian Li, Yuan Huang Small.2022;[Epub] CrossRef
FGFR3 Destabilizes PD-L1 via NEDD4 to Control T-cell–Mediated Bladder Cancer Immune Surveillance Weiqiang Jing, Ganyu Wang, Zhiwei Cui, Gaozhong Xiong, Xin Jiang, Yue Li, Wushan Li, Bo Han, Shouzhen Chen, Benkang Shi Cancer Research.2022; 82(1): 114. CrossRef
The immune modifying effects of chemotherapy and advances in chemo-immunotherapy Daniel R. Principe, Suneel D. Kamath, Murray Korc, Hidayatullah G. Munshi Pharmacology & Therapeutics.2022; 236: 108111. CrossRef
Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, phase II study S. Park, J.-M. Sun, Y.-L. Choi, D. Oh, H.K. Kim, T. Lee, S.A. Chi, S.-H. Lee, Y.S. Choi, S.-H. Jung, M.-J. Ahn, Y.C. Ahn, K. Park, Y.M. Shim ESMO Open.2022; 7(1): 100385. CrossRef
Analytical validation and initial clinical testing of quantitative microscopic evaluation for PD-L1 and HLA I expression on circulating tumor cells from patients with non-small cell lung cancer Jennifer L. Schehr, Nan Sethakorn, Zachery D. Schultz, Camila I. Hernandez, Rory M. Bade, Diego Eyzaguirre, Anupama Singh, David J. Niles, Leslie Henderson, Jay W. Warrick, Scott M. Berry, Kaitlin E. Sundling, David J. Beebe, Ticiana A. Leal, Joshua M. La Biomarker Research.2022;[Epub] CrossRef
Translational Learnings in the Development of Chemo-Immunotherapy Combination to Bypass the Cold Tumor Microenvironment in Pancreatic Ductal Adenocarcinoma Hélène Kaplon Frontiers in Oncology.2022;[Epub] CrossRef
Cost-effectiveness analyses of durvalumab consolidation therapy versus no consolidation therapy after chemoradiotherapy in stage-III NSCLC Salman Hussain, Jitka Klugarova, Miloslav Klugar Lung Cancer.2022; 170: 11. CrossRef
Efficacy comparison of immune treating strategies for NSCLC patients with negative PD-L1 expression Kaiyue Ding, Minhan Yi, Hui Liang, Zhongkui Li, Yuan Zhang Expert Review of Clinical Immunology.2022; 18(7): 759. CrossRef
Dual inhibition of TGFβ signaling and CSF1/CSF1R reprograms tumor-infiltrating macrophages and improves response to chemotherapy via suppressing PD-L1 Tsung-Wei Chen, Wei-Ze Hung, Shu-Fen Chiang, William Tzu-Liang Chen, Tao-Wei Ke, Ji-An Liang, Chih-Yang Huang, Pei-Chen Yang, Kevin Chih-Yang Huang, K.S. Clifford Chao Cancer Letters.2022; 543: 215795. CrossRef
SP142 PD-L1 Assays in Multiple Samples from the Same Patients with Early or Advanced Triple-Negative Breast Cancer Seung Ho Baek, Jee Hung Kim, Soong June Bae, Jung Hwan Ji, Yangkyu Lee, Joon Jeong, Yoon Jin Cha, Sung Gwe Ahn Cancers.2022; 14(13): 3042. CrossRef
Case Report: Sustained complete remission on combination therapy with olaparib and pembrolizumab in BRCA2-mutated and PD-L1-positive metastatic cholangiocarcinoma after platinum derivate Taotao Zhou, Robert Mahn, Christian Möhring, Farsaneh Sadeghlar, Carsten Meyer, Marieta Toma, Barbara Kreppel, Markus Essler, Tim Glowka, Hanno Matthaei, Jörg C. Kalff, Christian P. Strassburg, Maria A. Gonzalez-Carmona Frontiers in Oncology.2022;[Epub] CrossRef
Is there a place for chemotherapy in first line of treatment for metastatic NSCLC in era of immunotherapy? D. I. Yudin, K. K. Laktionov Medical alphabet.2022; (13): 18. CrossRef
The effect of neoadjuvant therapy on PD-L1 expression and CD8+lymphocyte density in non-small cell lung cancer Philipp Zens, Corina Bello, Amina Scherz, Michael von Gunten, Adrian Ochsenbein, Ralph A. Schmid, Sabina Berezowska Modern Pathology.2022; 35(12): 1848. CrossRef
MicroRNAs and Drug Resistance in Non-Small Cell Lung Cancer: Where Are We Now and Where Are We Going Roberto Cuttano, Miriam Kuku Afanga, Fabrizio Bianchi Cancers.2022; 14(23): 5731. CrossRef
miRNome profiling of lung cancer metastases revealed a key role for miRNA-PD-L1 axis in the modulation of chemotherapy response Roberto Cuttano, Tommaso Colangelo, Juliana Guarize, Elisa Dama, Maria Pia Cocomazzi, Francesco Mazzarelli, Valentina Melocchi, Orazio Palumbo, Elena Marino, Elena Belloni, Francesca Montani, Manuela Vecchi, Massimo Barberis, Paolo Graziano, Andrea Pasqui Journal of Hematology & Oncology.2022;[Epub] CrossRef
PD‐1 blockade using pembrolizumab in adolescent and young adult patients with advanced bone and soft tissue sarcoma Tahlia Scheinberg, Anna Lomax, Martin Tattersall, David Thomas, Geoff McCowage, Michael Sullivan, Rooshdiya Karim, Peter P. Luk, Annabelle Mahar, Fiona Bonar, Vivek A. Bhadri Cancer Reports.2021;[Epub] CrossRef
PD‐L1 versus tumor mutation burden: Which is the better immunotherapy biomarker in advanced non‐small cell lung cancer? Aoran Dong, Yiming Zhao, Zhihua Li, Hai Hu The Journal of Gene Medicine.2021;[Epub] CrossRef
Biomarkers predicting the response to chemotherapy and the prognosis in patients with esophageal squamous cell carcinoma Seiya Inoue, Takahiro Yoshida, Takeshi Nishino, Masakazu Goto, Mariko Aoyama, Naoya Kawakita, Yota Yamamoto, Furukita Yoshihito, Hiromitsu Takizawa, Akira Tangoku General Thoracic and Cardiovascular Surgery.2021; 69(3): 525. CrossRef
Patient-Reported Outcomes with Durvalumab by PD-L1 Expression and Prior Chemoradiotherapy-Related Variables in Unresectable Stage III Non-Small-Cell Lung Cancer Marina C Garassino, Luis Paz-Ares, Rina Hui, Corinne Faivre-Finn, Alex Spira, David Planchard, Mustafa Özgüroğlu, Davey Daniel, David Vicente, Shuji Murakami, Corey Langer, Suresh Senan, David Spigel, Anna Rydén, Yiduo Zhang, Cathy O'Brien, Phillip A Denn Future Oncology.2021; 17(10): 1165. CrossRef
Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer S. Sugawara, J.-S. Lee, J.-H. Kang, H.R. Kim, N. Inui, T. Hida, K.H. Lee, T. Yoshida, H. Tanaka, C.-T. Yang, M. Nishio, Y. Ohe, T. Tamura, N. Yamamoto, C.-J. Yu, H. Akamatsu, Y. Namba, N. Sumiyoshi, K. Nakagawa Annals of Oncology.2021; 32(9): 1137. CrossRef
Temporal evolution of programmed death-ligand 1 expression in patients with non-small cell lung cancer Chang Hyun Nam, Jaemoon Koh, Chan-Young Ock, Miso Kim, Bhumsuk Keam, Tae Min Kim, Yoon Kyung Jeon, Dong-Wan Kim, Doo Hyun Chung, Dae Seog Heo The Korean Journal of Internal Medicine.2021; 36(4): 975. CrossRef
Methylseleninic acid overcomes programmed death‐ligand 1‐mediated resistance of prostate cancer and lung cancer Wenli Hu, Yurong Ma, Chong Zhao, Shutao Yin, Hongbo Hu Molecular Carcinogenesis.2021; 60(11): 746. CrossRef
Immunological Status of Bladder Cancer Patients Based on Urine Leukocyte Composition at Radical Cystectomy Elisabet Cantó, Óscar Rodríguez Faba, Carlos Zamora, Maria Mulet, Maria Soledad Garcia-Cuerva, Ana Palomino, Georgia Anguera, Alberto Breda, Pablo Maroto, Sílvia Vidal Biomedicines.2021; 9(9): 1125. CrossRef
Ex vivo expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells through different receptor-ligand interactions Daun Jung, Young Seok Baek, In Jee Lee, Ki Yeon Kim, Heejoo Jang, Sohyun Hwang, Jieun Jung, Yong-wha Moon, Kyung-Soon Park, Yong-Soo Choi, Hee Jung An Journal of Experimental & Clinical Cancer Research.2021;[Epub] CrossRef
Prognostic significance of T‐cell–inflamed gene expression profile and PD‐L1 expression in patients with esophageal cancer Torben Steiniche, Sun Young Rha, Hyun Cheol Chung, Jeanette Baehr Georgsen, Morten Ladekarl, Marianne Nordsmark, Marie Louise Jespersen, Hyo Song Kim, Hyunki Kim, Carly Fein, Laura H. Tang, Ting Wu, Matthew J. Marton, Senaka Peter, David P. Kelsen, Geoffr Cancer Medicine.2021; 10(23): 8365. CrossRef
A novel form of immunotherapy using antigen peptides conjugated on PD-L1 antibody Eun Ji Lee, Gun-Young Jang, Sung Eun Lee, Ji won Lee, Hee Dong Han, Yeong-Min Park, Tae Heung Kang Immunology Letters.2021;[Epub] CrossRef
Assessment of the expression of the immune checkpoint molecules PD‐1, CTLA4, TIM‐3 and LAG‐3 across different cancers in relation to treatment response, tumor‐infiltrating immune cells and survival Lei Tu, Renguo Guan, Hanting Yang, Yu Zhou, Weifeng Hong, Liheng Ma, Guangzhe Zhao, Min Yu International Journal of Cancer.2020; 147(2): 423. CrossRef
Smokers or non-smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysis Jiahang Mo, Xiao Hu, Lihu Gu, Bangsheng Chen, Parikshit Asutosh Khadaroo, Zefeng Shen, Lei Dong, Yuqi Lv, Marylin Nyaradzo Chitumba, Jiequan Liu World Journal of Surgical Oncology.2020;[Epub] CrossRef
Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy Kathrin Gennen, Lukas Käsmann, Julian Taugner, Chukwuka Eze, Monika Karin, Olarn Roengvoraphoj, Jens Neumann, Amanda Tufman, Michael Orth, Simone Reu, Claus Belka, Farkhad Manapov Radiation Oncology.2020;[Epub] CrossRef
PD-L1 induction in tumor tissue after hypofractionated thoracic radiotherapy for non-small cell lung cancer Jaanika Narits, Hannes Tamm, Jana Jaal Clinical and Translational Radiation Oncology.2020; 22: 83. CrossRef
Variation of PD-L1 expression in locally advanced cervical cancer following neoadjuvant chemotherapy Yun Liang, Minghua Yu, Caiyun Zhou, Xiaojun Zhu Diagnostic Pathology.2020;[Epub] CrossRef
Application of immune checkpoint inhibitors in EGFR-mutant non-small-cell lung cancer: from bed to bench Rui Jin, Jing Zhao, Lexin Xia, Qin Li, Wen Li, Ling Peng, Yang Xia Therapeutic Advances in Medical Oncology.2020;[Epub] CrossRef
Independent Prognostic Value of Intratumoral Heterogeneity and Immune Response Features by Automated Digital Immunohistochemistry Analysis in Early Hormone Receptor-Positive Breast Carcinoma Dovile Zilenaite, Allan Rasmusson, Renaldas Augulis, Justinas Besusparis, Aida Laurinaviciene, Benoit Plancoulaine, Valerijus Ostapenko, Arvydas Laurinavicius Frontiers in Oncology.2020;[Epub] CrossRef
Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors Lorenzo Galluzzi, Juliette Humeau, Aitziber Buqué, Laurence Zitvogel, Guido Kroemer Nature Reviews Clinical Oncology.2020; 17(12): 725. CrossRef
Re-biopsy after first line treatment in advanced NSCLC can reveal changes in PD-L1 expression Malene Støchkel Frank, Uffe Bødtger, Asbjørn Høegholm, Inger Merete Stamp, Julie Gehl Lung Cancer.2020; 149: 23. CrossRef
The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players? Giuseppe Lamberti, Monia Sisi, Elisa Andrini, Arianna Palladini, Francesca Giunchi, Pier-Luigi Lollini, Andrea Ardizzoni, Francesco Gelsomino Cancers.2020; 12(11): 3129. CrossRef
The Dichotomous Role of Bone Marrow Derived Cells in the Chemotherapy-Treated Tumor Microenvironment Avital Vorontsova, Tal Kan, Ziv Raviv, Yuval Shaked Journal of Clinical Medicine.2020; 9(12): 3912. CrossRef
Adjuvant Chemotherapy Increases Programmed Death-Ligand 1 (PD-L1) Expression in Non–small Cell Lung Cancer Recurrence Max Lacour, Stefanie Hiltbrunner, Seok-Yun Lee, Alex Soltermann, Elisabeth Jane Rushing, Davide Soldini, Walter Weder, Alessandra Curioni-Fontecedro Clinical Lung Cancer.2019; 20(5): 391. CrossRef
PD-L1 Testing in Non-small Cell Lung Cancer: Past, Present, and Future Hyojin Kim, Jin-Haeng Chung Journal of Pathology and Translational Medicine.2019; 53(4): 199. CrossRef
Min Hwan Kim, Xianglan Zhang, Minkyu Jung, Inkyung Jung, Hyung Soon Park, Seung-Hoon Beom, Hyo Song Kim, Sun Young Rha, Hyunki Kim, Yoon Young Choi, Taeil Son, Hyoung-Il Kim, Jae-Ho Cheong, Woo Jin Hyung, Sung Hoon Noh, Hyun Cheol Chung
Cancer Res Treat. 2019;51(2):819-831. Published online September 27, 2018
Purpose
Identification of biomarkers to predict recurrence risk is essential to improve adjuvant treatment strategies in stage II/III gastric cancer patients. This study evaluated biomarkers for predicting survival after surgical resection.
Materials and Methods
This post-hoc analysis evaluated patients from the CLASSIC trial who underwent D2 gastrectomy with or without adjuvant chemotherapy (capecitabine plus oxaliplatin) at the Yonsei Cancer Center. Tumor expressions of thymidylate synthase (TS), excision repair cross-complementation group 1 (ERCC1), and programmed death-ligand 1 (PD-L1) were evaluated by immunohistochemical (IHC) staining to determine their predictive values.
Results
Among 139 patients, IHC analysis revealed high tumor expression of TS (n=22, 15.8%), ERCC1 (n=23, 16.5%), and PD-L1 (n=42, 30.2%) in the subset of patients. Among all patients, high TS expression tended to predict poor disease-free survival (DFS; hazard ratio [HR], 1.80; p=0.053), whereas PD-L1 positivity was associated with favorable DFS (HR, 0.33; p=0.001) and overall survival (OS; HR, 0.38; p=0.009) in multivariate Cox analysis. In the subgroup analysis, poor DFS was independently predicted by high TS expression (HR, 2.51; p=0.022) in the adjuvant chemotherapy subgroup (n=66). High PD-L1 expression was associated with favorable DFS (HR, 0.25; p=0.011) and OS (HR, 0.22; p=0.015) only in the surgery-alone subgroup (n=73). The prognostic impact of high ERCC1 expression was not significant in the multivariate Cox analysis.
Conclusion
This study shows that high TS expression is a predictive factor for worse outcomes on capecitabine plus oxaliplatin adjuvant chemotherapy, whereas PD-L1 expression is a favorable prognostic factor in locally advanced gastric cancer patients.
Citations
Citations to this article as recorded by
Utility of TMPRSS4 as a Prognostic Biomarker and Potential Therapeutic Target in Patients with Gastric Cancer Hirofumi Tazawa, Takahisa Suzuki, Akihisa Saito, Akira Ishikawa, Toshiaki Komo, Haruki Sada, Norimitsu Shimada, Naoto Hadano, Takashi Onoe, Takeshi Sudo, Yosuke Shimizu, Kazuya Kuraoka, Hirotaka Tashiro Journal of Gastrointestinal Surgery.2022; 26(2): 305. CrossRef
Scoring systems for PD-L1 expression and their prognostic impact in patients with resectable gastric cancer Marina Alessandra Pereira, Marcus Fernando Kodama Pertille Ramos, André Roncon Dias, Renan Ribeiro, Leonardo Cardili, Bruno Zilberstein, Ivan Cecconello, Ulysses Ribeiro, Evandro Sobroza de Mello, Tiago Biachi de Castria Virchows Archiv.2021; 478(6): 1039. CrossRef
Epstein–Barr Virus Positive Gastric Cancer: A Distinct Subtype Candidate for Immunotherapy Marina Alessandra Pereira, Daniel Amadeus Molon Batista, Marcus Fernando Kodama Pertille Ramos, Leonardo Cardili, Renan Ribeiro e Ribeiro, Andre Roncon Dias, Bruno Zilberstein, Ulysses Ribeiro Jr, Ivan Cecconello, Venâncio Avancini Ferreira Alves, Evandro Journal of Surgical Research.2021; 261: 130. CrossRef
Cytotoxic T‐lymphocyte‐associated protein 4 in gastric cancer: Prognosis and association with PD‐L1 expression Marina Alessandra Pereira, Tiago Biachi de Castria, Marcus Fernando Kodama Pertille Ramos, André Roncon Dias, Leonardo Cardili, Rafael Dyer Rodrigues de Moraes, Bruno Zilberstein, Sergio Carlos Nahas, Ulysses Ribeiro, Evandro Sobroza de Mello Journal of Surgical Oncology.2021; 124(7): 1040. CrossRef
Remnant gastric cancer: a neglected group with high potential for immunotherapy Marcus Fernando Kodama Pertille Ramos, Marina Alessandra Pereira, Tiago Biachi de Castria, Renan Ribeiro e Ribeiro, Leonardo Cardili, Evandro Sobroza de Mello, Bruno Zilberstein, Ulysses Ribeiro-Júnior, Ivan Cecconello Journal of Cancer Research and Clinical Oncology.2020; 146(12): 3373. CrossRef
Molecular Bases of Mechanisms Accounting for Drug Resistance in Gastric Adenocarcinoma Jose J. G. Marin, Laura Perez-Silva, Rocio I. R. Macias, Maitane Asensio, Ana Peleteiro-Vigil, Anabel Sanchez-Martin, Candela Cives-Losada, Paula Sanchon-Sanchez, Beatriz Sanchez De Blas, Elisa Herraez, Oscar Briz, Elisa Lozano Cancers.2020; 12(8): 2116. CrossRef
Clinical Significance of CLDN18.2 Expression in Metastatic Diffuse-Type Gastric Cancer Seo Ree Kim, Kabsoo Shin, Jae Myung Park, Han Hong Lee, Kyo Yong Song, Sung Hak Lee, Bohyun Kim, Sang-Yeob Kim, Junyoung Seo, Jeong-Oh Kim, Sang-Young Roh, In-Ho Kim Journal of Gastric Cancer.2020; 20(4): 408. CrossRef
Prognostic and Predictive Factors for the Curative Treatment of Esophageal and Gastric Cancer in Randomized Controlled Trials: A Systematic Review and Meta-Analysis van den Ende, ter Veer, Mali, van Berge Henegouwen, Hulshof, van Oijen, van Laarhoven Cancers.2019; 11(4): 530. CrossRef
Purpose
Tumor-infiltrating lymphocyte (TIL), programmed death-ligand 1 (PD-L1) expression and neutrophil-to-lymphocyte ratio (NLR) is associated to immunogenicity and prognosis of breast cancer. We analyzed baseline NLR, changes of NLR, TIL, and PD-L1 during neoadjuvant chemotherapy (NAC) and their clinical implication in triple-negative breast cancer (TNBC).
Materials and Methods
Between January 2008 to December 2015, 358 TNBC patients were analyzed. Baseline NLR, 50 paired NLR (initial diagnosis, after completion of NAC) and 34 paired tissues (initial diagnosis, surgical specimen after completion of NAC) were collected. Changes of TIL, CD4, CD8, forkhead box P3 (FOXP3), and PD-L1 expression were assessed with immunohistochemical stain.
Results
Low NLR (≤ 3.16) was associated to superior survival (overall survival: 41.83 months vs. 36.5 months, p=0.002; disease-free survival [DFS]: 37.85 months vs. 32.14 months, p=0.032). Modest NLR change after NAC (–30% < NLR change < 100%) showed prolonged DFS (38.37 months vs. 22.37 months, p=0.015). During NAC, negative or negative conversion of tumor PD-L1 expression was associated to poor DFS (34.77 months vs. 16.03 months, p=0.037), and same or increased TIL showed trends for superior DFS, but without statistical significance. Positive tumor PD-L1 expression (H-score ≥ 5) in baseline or post- NAC tissue was associated to superior DFS (57.6 months vs. 12.5 months, p=0.001 and 53.3 months vs. 18.9 months, p=0.040). Positive stromal PD-L1 expression in baseline was also associated to superior DFS (50.2 months vs. 20.4 months, p=0.002).
Conclusion
In locally advanced TNBC, baseline NLR, changes of NLR during NAC was associated to survival. Baseline PD-L1 expression and changes of PD-L1 expression in tumor tissue during NAC also showed association to prognosis.
Citations
Citations to this article as recorded by
Neutrophil–lymphocyte ratio reflects tumour‐infiltrating lymphocytes and tumour‐associated macrophages and independently predicts poor outcome in breast cancers with neoadjuvant chemotherapy Joshua J X Li, Shelly Y B Ni, Julia Y S Tsang, Wai Yin Chan, Ray K W Hung, Joshua W H Lui, Sally W Y Ng, Leong Kwong Shum, Ying Fei Tang, Gary M Tse Histopathology.2024; 84(5): 810. CrossRef
Circulating blood biomarkers correlated with the prognosis of advanced triple negative breast cancer Xingyu Li, Yanyan Zhang, Cheng Zhu, Wentao Xu, Xiaolei Hu, Domingo Antonio Sánchez Martínez, José Luis Alonso Romero, Ming Yan, Ying Dai, Hua Wang BMC Women's Health.2024;[Epub] CrossRef
Recent advancements in nanoconstructs for the theranostics applications for triple negative breast cancer Ashutosh Gupta, Kumar Nishchaya, Moumita Saha, Gaurisha Alias Resha Ramnath Naik, Sarika Yadav, Shreya Srivastava, Amrita Arup Roy, Sudheer Moorkoth, Srinivas Mutalik, Namdev Dhas Journal of Drug Delivery Science and Technology.2024; 93: 105401. CrossRef
Predictive value of stromal tumor-infiltrating lymphocytes in patients with breast cancer treated with neoadjuvant chemotherapy: A meta-analysis Guangfa Xia, Ziran Zhang, Qin Jiang, Huan Wang, Jie Wang Medicine.2024; 103(6): e36810. CrossRef
The prognostic value of preoperative neoindices consisting of lymphocytes, neutrophils and albumin (LANR) in operable breast cancer: a retrospective study Yuan Wang, Jiaru Zhuang, Shan Wang, Yibo Wu, Ling Chen PeerJ.2024; 12: e17382. CrossRef
A review concerning the breast cancer-related tumour microenvironment Oscar Hernán Rodríguez-Bejarano, Carlos Parra-López, Manuel Alfonso Patarroyo Critical Reviews in Oncology/Hematology.2024; 199: 104389. CrossRef
Alteration of PD-L1 (SP142) status after neoadjuvant chemotherapy and its clinical significance in triple-negative breast cancer Ji Won Woo, Eun Kyung Han, Koung Jin Suh, Se Hyun Kim, Jee Hyun Kim, So Yeon Park Breast Cancer Research and Treatment.2024; 207(2): 301. CrossRef
Predictive value of pretreatment circulating inflammatory response markers in the neoadjuvant treatment of breast cancer: meta-analysis Gavin P Dowling, Gordon R Daly, Aisling Hegarty, Sandra Hembrecht, Aisling Bracken, Sinead Toomey, Bryan T Hennessy, Arnold D K Hill British Journal of Surgery.2024;[Epub] CrossRef
Pathology of neoadjuvant therapy and immunotherapy testing for breast cancer Elena Provenzano, Abeer M Shaaban Histopathology.2023; 82(1): 170. CrossRef
Recent Advances in Targeted Nanocarriers for the Management of Triple Negative Breast Cancer Rajesh Pradhan, Anuradha Dey, Rajeev Taliyan, Anu Puri, Sanskruti Kharavtekar, Sunil Kumar Dubey Pharmaceutics.2023; 15(1): 246. CrossRef
The prognostic value of tumour-infiltrating lymphocytes, programmed cell death protein-1 and programmed cell death ligand-1 in Stage I–III triple-negative breast cancer Guang-Yi Sun, Jing Zhang, Bing-Zhi Wang, Hao Jing, Hui Fang, Yu Tang, Yong-Wen Song, Jing Jin, Yue-Ping Liu, Yuan Tang, Shu-Nan Qi, Bo Chen, Ning-Ning Lu, Ning Li, Ye-Xiong Li, Jian-Ming Ying, Shu-Lian Wang British Journal of Cancer.2023; 128(11): 2044. CrossRef
Effect of neoadjuvant chemotherapy on tumor immune infiltration in breast cancer patients: Systematic review and meta-analysis Manuela Llano-León, Laura Camila Martínez-Enriquez, Oscar Mauricio Rodríguez-Bohórquez, Esteban Alejandro Velandia-Vargas, Nicolás Lalinde-Ruíz, María Alejandra Villota-Álava, Ivon Johanna Rodríguez-Rodríguez, María del Pilar Montilla-Velásquez, Carlos Al PLOS ONE.2023; 18(4): e0277714. CrossRef
Association of neutrophil-to-lymphocyte ratio with clinical, pathological, radiological, laboratory features and disease outcomes of invasive breast cancer patients: A retrospective observational cohort study Sarosh Khan Jadoon, Rufina Soomro, Muhammad Nadeem Ahsan, Raja Muhammad Ijaz Khan, Sadia Iqbal, Farah Yasmin, Hala Najeeb, Nida Saleem, Namiya Cho, Resham, Taha Gul Shaikh, Syeda Fatima Saba Hasan, Muhammad Zain Khalid, Sarosh Alvi, Ahsan Mujtaba Rizvi, Medicine.2023; 102(20): e33811. CrossRef
A new prognostic model including immune biomarkers, genomic proliferation tumor markers (AURKA and MYBL2) and clinical-pathological features optimizes prognosis in neoadjuvant breast cancer patients Esmeralda García-Torralba, Esther Navarro Manzano, Gines Luengo-Gil, Pilar De la Morena Barrio, Asunción Chaves Benito, Miguel Pérez-Ramos, Beatriz Álvarez-Abril, Alejandra Ivars Rubio, Elisa García-Garre, Francisco Ayala de la Peña, Elena García-Martínez Frontiers in Oncology.2023;[Epub] CrossRef
Tumor infiltrating lymphocytes and neutrophil-to-lymphocyte ratio in relation to pathological complete remission to neoadjuvant therapy and prognosis in triple negative breast cancer Meng Zhao, Hui Xing, Jiankun He, Xinran Wang, Yueping Liu Pathology - Research and Practice.2023; 248: 154687. CrossRef
Minimal residual disease in advanced or metastatic solid cancers: The G0-G1 state and immunotherapy are key to unwinding cancer complexity Andrea Nicolini, Giuseppe Rossi, Paola Ferrari, Angelo Carpi Seminars in Cancer Biology.2022; 79: 68. CrossRef
The advanced lung cancer inflammation index is a novel independent prognosticator in colorectal cancer patients after curative resection Taichi Horino, Ryuma Tokunaga, Yuji Miyamoto, Yukiharu Hiyoshi, Takahiko Akiyama, Nobuya Daitoku, Yuki Sakamoto, Naoya Yoshida, Hideo Baba Annals of Gastroenterological Surgery.2022; 6(1): 83. CrossRef
The Characteristics of Tumor Microenvironment in Triple Negative Breast Cancer Yiqi Fan, Shuai He Cancer Management and Research.2022; Volume 14: 1. CrossRef
Predictive and Prognostic Role of Peripheral Blood T-Cell Subsets in Triple-Negative Breast Cancer Meng Li, Junnan Xu, Cui Jiang, Jingyan Zhang, Tao Sun Frontiers in Oncology.2022;[Epub] CrossRef
PD-L1 expression in breast invasive ductal carcinoma with incomplete pathological response to neoadjuvant chemotherapy Ahmad Alhesa, Heyam Awad, Sarah Bloukh, Mahmoud Al-Balas, Mohammed El-Sadoni, Duaa Qattan, Bilal Azab, Tareq Saleh International Journal of Immunopathology and Pharmacology.2022;[Epub] CrossRef
Circulating proteins as predictive and prognostic biomarkers in breast cancer Hugo Veyssière, Yannick Bidet, Frederique Penault-Llorca, Nina Radosevic-Robin, Xavier Durando Clinical Proteomics.2022;[Epub] CrossRef
Targeting the antigen processing and presentation pathway to overcome resistance to immune checkpoint therapy Silvia D’Amico, Patrizia Tempora, Ombretta Melaiu, Valeria Lucarini, Loredana Cifaldi, Franco Locatelli, Doriana Fruci Frontiers in Immunology.2022;[Epub] CrossRef
Programmed death-ligand 1 (PD-L1) expression predicts response to neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis Hamdy A. Azim, Kyrillus S. Shohdy, Hagar Elghazawy, Monica M. Salib, Doaa Almeldin, Loay Kassem Biomarkers.2022; 27(8): 764. CrossRef
Determining Factors in the Therapeutic Success of Checkpoint Immunotherapies against PD-L1 in Breast Cancer: A Focus on Epithelial-Mesenchymal Transition Activation Mariana Segovia-Mendoza, Susana Romero-Garcia, Cristina Lemini, Heriberto Prado-Garcia, francesca bianchi Journal of Immunology Research.2021; 2021: 1. CrossRef
Kaiso (ZBTB33) subcellular partitioning functionally links LC3A/B, the tumor microenvironment, and breast cancer survival Sandeep K. Singhal, Jung S. Byun, Samson Park, Tingfen Yan, Ryan Yancey, Ambar Caban, Sara Gil Hernandez, Stephen M. Hewitt, Heike Boisvert, Stephanie Hennek, Mark Bobrow, Md Shakir Uddin Ahmed, Jason White, Clayton Yates, Andrew Aukerman, Rami Vanguri, R Communications Biology.2021;[Epub] CrossRef
Relationship Between the Neutrophil to Lymphocyte Ratio, Stromal Tumor-infiltrating Lymphocytes, and the Prognosis and Response to Neoadjuvant Chemotherapy in Triple-negative Breast Cancer Jian Pang, Haiyan Zhou, Xue Dong, Shouman Wang, Zhi Xiao Clinical Breast Cancer.2021; 21(6): e681. CrossRef
Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial Monika Graeser, Friedrich Feuerhake, Oleg Gluz, Valery Volk, Michael Hauptmann, Katarzyna Jozwiak, Matthias Christgen, Sherko Kuemmel, Eva-Maria Grischke, Helmut Forstbauer, Michael Braun, Mathias Warm, John Hackmann, Christoph Uleer, Bahriye Aktas, Claud Journal for ImmunoTherapy of Cancer.2021; 9(5): e002198. CrossRef
Clinicopathological and prognostic significance of programmed cell death ligand 1 expression in patients diagnosed with breast cancer: meta-analysis M G Davey, É J Ryan, M S Davey, A J Lowery, N Miller, M J Kerin British Journal of Surgery.2021; 108(6): 622. CrossRef
INSTIGO Trial: Evaluation of a Plasma Protein Profile as a Predictive Biomarker for Metastatic Relapse of Triple Negative Breast Cancer Hugo Veyssière, Sejdi Lusho, Ioana Molnar, Myriam Kossai, Maureen Bernadach, Catherine Abrial, Yannick Bidet, Nina Radosevic-Robin, Xavier Durando Frontiers in Oncology.2021;[Epub] CrossRef
Inhibitors of PD-1/PD-L1 and ERK1/2 impede the proliferation of receptor positive and triple-negative breast cancer cell lines Karen Bräutigam, Elodie Kabore-Wolff, Ahmad Fawzi Hussain, Stephan Polack, Achim Rody, Lars Hanker, Frank Köster Journal of Cancer Research and Clinical Oncology.2021; 147(10): 2923. CrossRef
Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting Antonino Grassadonia, Vincenzo Graziano, Laura Iezzi, Patrizia Vici, Maddalena Barba, Laura Pizzuti, Giuseppe Cicero, Eriseld Krasniqi, Marco Mazzotta, Daniele Marinelli, Antonella Amodio, Clara Natoli, Nicola Tinari Cells.2021; 10(7): 1685. CrossRef
Time-Sequencing of the Neutrophil-to-Lymphocyte Ratio to Predict Prognosis of Triple-Negative Breast Cancer Joo-Heung Kim, Nak-Hoon Son, Jun-Sang Lee, Ji-Eun Mun, Jee-Ye Kim, Hyung-Seok Park, Seho Park, Seung-Il Kim, Byeong-Woo Park Cancers.2021; 13(14): 3472. CrossRef
Platelet-to-Lymphocyte Ratio Is Associated With Favorable Response to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: A Study on 120 Patients Sejdi Lusho, Xavier Durando, Marie-Ange Mouret-Reynier, Myriam Kossai, Nathalie Lacrampe, Ioana Molnar, Frederique Penault-Llorca, Nina Radosevic-Robin, Catherine Abrial Frontiers in Oncology.2021;[Epub] CrossRef
Role of neutrophil-to-lymphocyte ratio as a prognostic biomarker in patients with breast cancer receiving neoadjuvant chemotherapy: a meta-analysis Qiong Zhou, Jie Dong, Qingqing Sun, Nannan Lu, Yueyin Pan, Xinghua Han BMJ Open.2021; 11(9): e047957. CrossRef
Neutrophil to Lymphocyte Ratio after Treatment Completion as a Potential Predictor of Survival in Patients with Triple-Negative Breast Cancer Kwang-Min Kim, Hyang Suk Choi, Hany Noh, In-Jeong Cho, Seung Taek Lim, Jong-In Lee, Airi Han Journal of Breast Cancer.2021; 24(5): 443. CrossRef
Tumor Microenvironment Characterization in Breast Cancer Identifies Prognostic and Neoadjuvant Chemotherapy Relevant Signatures Fei Ji, Jiao-Mei Yuan, Hong-Fei Gao, Ai-Qi Xu, Zheng Yang, Ci-Qiu Yang, Liu-Lu Zhang, Mei Yang, Jie-Qing Li, Teng Zhu, Min-Yi Cheng, Si-Yan Wu, Kun Wang Frontiers in Molecular Biosciences.2021;[Epub] CrossRef
Neutrophil to Lymphocyte Ratio as Prognostic and Predictive Factor in Breast Cancer Patients: A Systematic Review Iléana Corbeau, William Jacot, Séverine Guiu Cancers.2020; 12(4): 958. CrossRef
A Rosetta Stone for Breast Cancer: Prognostic Value and Dynamic Regulation of Neutrophil in Tumor Microenvironment Wei Zhang, Yimin Shen, Huanhuan Huang, Sheng Pan, Jingxin Jiang, Wuzhen Chen, Ting Zhang, Chao Zhang, Chao Ni Frontiers in Immunology.2020;[Epub] CrossRef
Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies Gagan K. Gupta, Amber L. Collier, Dasom Lee, Richard A. Hoefer, Vasilena Zheleva, Lauren L. Siewertsz van Reesema, Angela M. Tang-Tan, Mary L. Guye, David Z. Chang, Janet S. Winston, Billur Samli, Rick J. Jansen, Emanuel F. Petricoin, Matthew P. Goetz, Ha Cancers.2020; 12(9): 2392. CrossRef
Prognostic Role and Clinical Significance of Tumor-Infiltrating Lymphocyte (TIL) and Programmed Death Ligand 1 (PD-L1) Expression in Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis Study Parisa Lotfinejad, Mohammad Asghari Jafarabadi, Mahdi Abdoli Shadbad, Tohid Kazemi, Fariba Pashazadeh, Siamak Sandoghchian Shotorbani, Farhad Jadidi Niaragh, Amir Baghbanzadeh, Nafiseh Vahed, Nicola Silvestris, Behzad Baradaran Diagnostics.2020; 10(9): 704. CrossRef
Prediction of Late Recurrence and Distant Metastasis in Early-stage Breast Cancer: Overview of Current and Emerging Biomarkers A. Gouri, B. Benarba, A. Dekaken, H. Aoures, S. Benharkat Current Drug Targets.2020; 21(10): 1008. CrossRef
Prognostic value of neutrophil‐to‐lymphocyte ratio and platelet‐to‐lymphocyte ratio for breast cancer patients: An updated meta‐analysis of 17079 individuals Wanying Guo, Xin Lu, Qipeng Liu, Ting Zhang, Peng Li, Weiqiang Qiao, Miao Deng Cancer Medicine.2019; 8(9): 4135. CrossRef
Prognostic and clinicopathological value of PD-L1 expression in primary breast cancer: a meta-analysis Wenfa Huang, Ran Ran, Bin Shao, Huiping Li Breast Cancer Research and Treatment.2019; 178(1): 17. CrossRef
Comparison of Preoperative Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios in Bladder Cancer Patients Undergoing Radical Cystectomy Ruiliang Wang, Yang Yan, Shenghua Liu, Xudong Yao BioMed Research International.2019; 2019: 1. CrossRef
Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives E. Krasniqi, G. Barchiesi, L. Pizzuti, M. Mazzotta, A. Venuti, M. Maugeri-Saccà, G. Sanguineti, G. Massimiani, D. Sergi, S. Carpano, P. Marchetti, S. Tomao, T. Gamucci, R. De Maria, F. Tomao, C. Natoli, N. Tinari, G. Ciliberto, M. Barba, P. Vici Journal of Hematology & Oncology.2019;[Epub] CrossRef
Prognostic Implications of PD-L1 Expression in Breast Cancer: Systematic Review and Meta-analysis of Immunohistochemistry and Pooled Analysis of Transcriptomic Data Alexios Matikas, Ioannis Zerdes, John Lövrot, François Richard, Christos Sotiriou, Jonas Bergh, Antonios Valachis, Theodoros Foukakis Clinical Cancer Research.2019; 25(18): 5717. CrossRef